To evaluate the effect of the treatment with nitric oxide (NO) donors in pregnant women with small-for-gestational age fetuses. Methods: 48 pregnant women referred for small for gestational age (SGA) fetus underwent a non-invasive hemodynamic measurement and an ultrasonic assessment of fetal growth. We obtained three subgroups according to total vascular resistance (TVR): Group A (high TVR treated, n=13), Group B (high TVR untreated, n=15) and Group C (low TVR untreated, n=20). After 4 weeks, we repeated fetal biometry and maternal cardiovascular assessment. Furthermore our aim was to identify those fetuses which turned their conditions to pathological intrauterine growth restriction (IUGR).
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Results:
In table 1, we reported maternal main hemodynamic parameters in the three groups after 4 weeks of treatment/no treatment. Our data demonstrated that SGA fetuses with high TVR under treatment showed an improvement of maternal hemodynamic parameters after 4 weeks (see graph). Group B patients showed an impaired hemodynamic pattern, having an increased risk to develop IUGR and other complications. Conclusions: Maternal hemodynamic assessment at diagnosis of a SGA fetus might identify patients at risk to turn to pathological growth restriction. The preventive use of NO donors has shown to improve the impaired cardiovascular pattern and fetal outcomes.
Supporting information can be found in the online version of this abstract OC09.02: Table 1. Objectives: The aim of this study was to describe pattern placental pathological findings in a large cohort of small-for-gestational age (SGA) newborns with and without pre-eclampsia (PE), as compared to uncomplicated pregnancies. Methods: A prospective cohort study of 145 uncomplicated pregnancies and 237 SGA newborns (defined by birth weight < 10th centile) including 95 cases associated to PE. Placental lesions were histologically categorised according to the 2015 Redline classification. Results: SGA cases associated with PE showed a higher prevalence of maternal lesions in the placenta including maldevelopment (controls 2.2% vs. SGA 2.5% vs. SGA+PE 16.2%, p< 0.001) and malperfusion (controls 28.4% vs. SGA 33.1% vs. SGA+PE 73.8%, p< 0.001), with a similar prevalence of fetal stromal-vascular lesions as compared to normotensive SGA and uncomplicated pregnancies. In contrast, normotensive SGA was significantly associated with fetal maldevelopment lesions (controls 3% vs. SGA 8.3% vs. SGA+PE 0%, p=0.009) with similar prevalence of maternal vascular-stromal lesions as compared to uncomplicated pregnancies. Conclusions: SGA+PE is predominantly associated with maternal stroma/vasculature lesions in the placenta while normotensive SGA is associated with fetal maldevelopment lesions. Comprehensive classification of placental lesions might help to better understand the pathophysiology underlying fetal growth restriction and PE.
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